FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361957734> ?p ?o ?g. }

• W4361957734 abstract "<div>Abstract<p><b>Purpose:</b> In addition to their direct cytopathic effects, oncolytic viruses are capable of priming antitumor immune responses. However, strategies to enhance the immunotherapeutic potential of these agents are lacking. Here, we investigated the ability of the multi-tyrosine kinase inhibitor and first-line metastatic renal cell carcinoma (RCC) agent, sunitinib, to augment the antitumor immune response generated by oncolytic reovirus.</p><p><b>Experimental Design:</b><i>In vitro</i>, oncolysis and chemokine production were assessed in a panel of human and murine RCC cell lines after exposure to reovirus, sunitinib, or their combination. <i>In vivo</i>, the RENCA syngeneic murine model of RCC was employed to determine therapeutic and tumor-specific immune responses after treatment with reovirus (intratumoral), sunitinib, or their combination. Parallel investigations employing the KLN205 syngeneic murine model of lung squamous cell carcinoma (NSCLC) were conducted for further validation.</p><p><b>Results:</b> Reovirus-mediated oncolysis and chemokine production was observed following RCC infection. Reovirus monotherapy reduced tumor burden and was capable of generating a systemic adaptive antitumor immune response evidenced by increased numbers of tumor-specific CD8⁺ IFNγ-producing cells. Coadministration of sunitinib with reovirus further reduced tumor burden resulting in improved survival, decreased accumulation of immune suppressor cells, and the establishment of protective immunity upon tumor rechallenge. Similar results were observed for KLN205 tumor–bearing mice, highlighting the potential broad applicability of this approach.</p><p><b>Conclusions:</b> The ability to repurpose sunitinib for augmentation of reovirus' immunotherapeutic efficacy positions this novel combination therapy as an attractive strategy ready for clinical testing against a range of histologies, including RCC and NSCLC. <i>Clin Cancer Res; 22(23); 5839–50. ©2016 AACR</i>.</p></div>" @default.
• W4361957734 created "2023-04-05" @default.
• W4361957734 creator A5000756748 @default.
• W4361957734 creator A5011184057 @default.
• W4361957734 creator A5022519239 @default.
• W4361957734 creator A5026626734 @default.
• W4361957734 creator A5031023868 @default.
• W4361957734 creator A5034922317 @default.
• W4361957734 creator A5048264099 @default.
• W4361957734 creator A5065014768 @default.
• W4361957734 creator A5066797726 @default.
• W4361957734 date "2023-03-31" @default.
• W4361957734 modified "2023-09-25" @default.
• W4361957734 title "Data from Repurposing Sunitinib with Oncolytic Reovirus as a Novel Immunotherapeutic Strategy for Renal Cell Carcinoma" @default.
• W4361957734 doi "https://doi.org/10.1158/1078-0432.c.6526563.v1" @default.
• W4361957734 hasPublicationYear "2023" @default.
• W4361957734 type Work @default.
• W4361957734 citedByCount "0" @default.
• W4361957734 crossrefType "posted-content" @default.
• W4361957734 hasAuthorship W4361957734A5000756748 @default.
• W4361957734 hasAuthorship W4361957734A5011184057 @default.
• W4361957734 hasAuthorship W4361957734A5022519239 @default.
• W4361957734 hasAuthorship W4361957734A5026626734 @default.
• W4361957734 hasAuthorship W4361957734A5031023868 @default.
• W4361957734 hasAuthorship W4361957734A5034922317 @default.
• W4361957734 hasAuthorship W4361957734A5048264099 @default.
• W4361957734 hasAuthorship W4361957734A5065014768 @default.
• W4361957734 hasAuthorship W4361957734A5066797726 @default.
• W4361957734 hasBestOaLocation W43619577342 @default.
• W4361957734 hasConcept C126322002 @default.
• W4361957734 hasConcept C13373296 @default.
• W4361957734 hasConcept C203014093 @default.
• W4361957734 hasConcept C2777472916 @default.
• W4361957734 hasConcept C2779490328 @default.
• W4361957734 hasConcept C502942594 @default.
• W4361957734 hasConcept C71924100 @default.
• W4361957734 hasConcept C82210918 @default.
• W4361957734 hasConcept C8891405 @default.
• W4361957734 hasConceptScore W4361957734C126322002 @default.
• W4361957734 hasConceptScore W4361957734C13373296 @default.
• W4361957734 hasConceptScore W4361957734C203014093 @default.
• W4361957734 hasConceptScore W4361957734C2777472916 @default.
• W4361957734 hasConceptScore W4361957734C2779490328 @default.
• W4361957734 hasConceptScore W4361957734C502942594 @default.
• W4361957734 hasConceptScore W4361957734C71924100 @default.
• W4361957734 hasConceptScore W4361957734C82210918 @default.
• W4361957734 hasConceptScore W4361957734C8891405 @default.
• W4361957734 hasLocation W43619577341 @default.
• W4361957734 hasLocation W43619577342 @default.
• W4361957734 hasOpenAccess W4361957734 @default.
• W4361957734 hasPrimaryLocation W43619577341 @default.
• W4361957734 hasRelatedWork W2005666125 @default.
• W4361957734 hasRelatedWork W2050374169 @default.
• W4361957734 hasRelatedWork W2075668427 @default.
• W4361957734 hasRelatedWork W2106908546 @default.
• W4361957734 hasRelatedWork W4361929458 @default.
• W4361957734 hasRelatedWork W4361930050 @default.
• W4361957734 hasRelatedWork W4362403010 @default.
• W4361957734 hasRelatedWork W4362403129 @default.
• W4361957734 hasRelatedWork W4362403495 @default.
• W4361957734 hasRelatedWork W960258928 @default.
• W4361957734 isParatext "false" @default.
• W4361957734 isRetracted "false" @default.
• W4361957734 workType "article" @default.